
New Market - September 23, 2019
Lundbeck and Takeda announce approval of Trintellix in Japan
The two companies jointly announced today that the MHLW of Japan approved Trintellix (vortioxetine) for the treatment of depression and depressed state. The NDA filing submitted to the MHLW in September 2018 included data from a phase III trial, which demonstrated statistically significant improvement in overall symptoms of depression in adults as compared to placebo. […]

Collaboration - August 29, 2017
AstraZeneca, Takeda collaborates on Parkinson’s disease drug
AstraZeneca and Takeda Pharmaceutical have entered an agreement to jointly develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD). Alpha-synuclein (α-synuclein) is an aggregation-prone protein that contributes to the development of PD. This protein is the major constituent of Lewy bodies, which are pathological protein aggregates […]

Acquisition - December 15, 2015
AstraZeneca acquires Takeda’s respiratory business
AstraZeneca has entered into a definitive agreement to acquire the core respiratory business of Takeda Pharmaceutical Company Limited. The deal will include the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD). AstraZeneca […]

Drug Development Pharma - October 9, 2013
Takeda and Lundbeck announce FDA approval of Brintellix
Takeda Pharmaceutical Company and H. Lundbeck A/S jointly have announced that the U.S. Food and Drug Administration (FDA) has approved Brintellix (vortioxetine) for the treatment of adults with major depressive disorder (MDD). “MDD is a multifaceted disorder that encompasses emotional, physical and cognitive symptoms that may make it challenging to treat,” said Michael Thase, M.D., […]